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Abstract 
Evasion of apoptosis is a hallmark of human cancer, and a desired endpoint of many 
anticancer agents is the induction of cell death. With the heterogeneity of cancer 
becoming increasingly apparent, to understand drug mechanisms of action and identify 
combination therapies in cell populations, the development of tools to assess drug 
effects at the single cell level is a necessity for future preclinical drug development. 
Herein we describe the development of pCasFSwitch, a genetically encoded reporter 
construct designed to identify cells undergoing caspase-3 mediated apoptosis, by a 
translocation of a GFP signal from the cell membrane into the nucleus. Anticipated 
cellular distribution was demonstrated by use of confocal microscopy and cleavage by 
caspase-3 was shown to be required for the translocation of the GFP signal seen in 
apoptotic cells. Quantification of apoptosis using the construct revealed similar levels 
to that obtained with a commercially available apoptosis imaging agent (22.6 % versus 
20.3%). Moreover, we demonstrated its capacity for use in a high-throughput setting 
making it a powerful tool for drug development pipelines. 
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1. Introduction 
 
Advances in fluorescent probe technology has seen the generation of an abundance of 
fluorescent probes or biosensors, which can be used to monitor complex cellular 
processes at a molecular level, such as small signaling molecule dynamics, protein-
protein interactions and enzyme activation. Engineered fluorescent probes are 
extremely powerful tools for elucidating molecular drug mechanisms, and with the 
development of a wealth of fluorophores this allows multiple events to be monitored 
simultaneously at the single cell level. At a time when the heterogeneity of cancer is 
becoming increasingly apparent, the need for evaluation of drug effects at this level is 
even more pressing, aiding the visualization of differential treatment responses within 
cell populations. 
Apoptosis (or programmed cell death) is an essential process required during 
embryogenesis and for the maintenance of normal tissue homeostasis. The evasion of 
cell death or apoptosis is also a hallmark of human cancer [1] with the desired endpoint 
of traditional cytotoxics and many molecularly targeted agents being the induction of 
cell death [2, 3]. Establishing a convenient and robust measurement of apoptosis at the 
single cell level in response to drug treatments would be a useful tool in preclinical drug 
development as we try and understand the complexities of drug mechanism of action 
and combination therapies. Caspases are a large family of cysteine proteases that play 
a central role in mediating the apoptotic response. To date, 11 human caspases have 
been identified: caspases-1-10 and -14 [4, 5]. Some caspases have evolved to link 
upstream signaling pathways to initiate apoptosis, while others execute the steps of cell 
death. Based on this function classification, caspases are classed as initiators (caspases- 
1, -2, -4, -5, -8, -9, -10, -11, -12) or executioners (caspases-3, -6 and -7). All caspases 
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are synthesized as inactive zymogens whose activation is mediated by either a series of 
cleavage events or allosteric conformational changes [6, 7]. To enable the specific 
evaluation of apoptotic cell death attention is being focused on the use of caspase 
activation as the target for fluorescent imaging agents. Specifically, caspase-3 is 
considered to be the central effector caspase since it is activated during the early stages 
of apoptosis during both the intrinsic and extrinsic caspase signaling cascade [8]. 
Activated caspase-3 recognizes a sequence of four amino acids (DEVD) in a number 
of target proteins such as cytokeratins and poly (ADP-ribose) polymerase (PARP) 
whose cleavage leads to cell death. To date caspase-3 activation as an indicator of 
apoptosis has been measured using a number of different approaches. One approach 
has been the use of fluorescence resonance energy transfer (FRET) pairs linked by 
caspase cleavage sequences such as DEVD, which allows measurement of caspase 
activation in single cells [9, 10]. Other methodologies have used either loss of 
fluorescence quenching, switching-on of fluorescence or translocation of fluorescent 
proteins following caspase cleavage to monitor apoptosis [11-16]. Here we describe the 
generation of a novel genetically encoded caspase-3 reporter which is based on the 
translocation of GFP from the plasma membrane to the nucleus following cleavage of 
the DEVDG peptide sequence allowing quantitative measurements of apoptosis at the 
single cell level.    
 
 
2. Experimental 
 
2.1 Generation of constructs 
pEGFP-N1 (https://www.addgene.org/vector-database/2491/) was digested with Xho1 
and BamH1 and ligated with forward (F) and reverse (R) single-stranded synthetic NLS 
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oligonucleotides (Table 1). Following transformation of competent E. coli and DNA 
purification, positive clones containing the NLS insert were identified by Xho1 and 
BamH1 digestion and agarose-gel electrophoresis. The above process was repeated to 
sequentially insert the PLS oligonucleotides (using BsrG1 and Not1) and the DEVDG 
oligonucleotides (BsrG1 and EcoRV). Resulting pNGD6 and pNGDH constructs were 
Sanger sequenced using primers 5’GTCGCCGTCCAGCTCGACCAG3’ and 
5’CATGGTCCTGCTGGAGTTCGTG3’ respectively. For generation of pNGNH and 
pNGNH mutants, site directed mutagenesis was carried out using F (5’ 
GTGACGAGGTCAACGGTACCTCAGTC 3’) and R (5’ 
GACTGAGGTACCGTTGACCTCGTCAC 3’) primers and Sanger sequenced using 
primer 5’ TGAACTTCAAGATCCGCCAC 3’ to ensure mutation of the construct. 
NGD6 and NGN6 were then introduced into pBABEpuro retroviral vector. Blunt-end PCR 
products were generated by combining 10 ng of construct with 100 ng F (5’ 
TACGTAATGGATCCAAAAAAG 3’) and R (5’ GCGGCCGCTTACATAATTAC 3’) 
primers in PfuUltra Hotstart PCR Master Mix (Agilent Technologies). Purified DNA was 
cloned into TOPO using the Zero Blunt Topo PCR cloning kit (Invitrogen). DNA and pBABE 
vector was digested using SnaB1 and EcoR1 restriction endonucleases. Inserts digested from 
pCRII-Blunt-Topo were purified alongside the digested pBABE using QIAquick Gel extraction 
kit. Insert and vector were ligated using Rapid DNA ligation kit (Roche) before proceeding to 
bacterial transformation, amplification, and extraction using Qiagen Plasmid Plus Maxi Kit. 
Constructs were Sanger sequenced using primers 5’ TACGGCGTGCAGTGCTTCAG 3’, 
5’CTGAAGCACTGCACGCCGTA3’, 5’TGAACTTCAAGATCCGCCAC3’, 
5’GTGGCGGATCTTGAAGTTCA3’, 5’AAGGGCGAGGAGCTGTTCAC3’, 
5’GTGAACAGCTCCTCGCCCTT3’, 5’ATCACTCTCGGCATGGACGA3’, 
5’TCGTCCATGCCGAGAGTGAT3’. 	
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Table 1: Oligonucleotide sequences. Oligonucleotide nomenclature and sequences 
used for the generation of the in-house apoptosis imaging agent. F and R denote forward 
and reverse oligonucleotide respectively. Oligonucleotides were dissolved in 100 µl of 
dH20. All oligonucleotides were purchased from Invitrogen. 
NAME F / R SEQUENCE 5’ – 3’ 
2NLS F 
TCGAGATGGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGGATCCACCGGATCTAGA 
R GATCTCTAGATCCGGTGGATCCTACCTTTCTCTTCTTTTTTGGATCTACCTTTCTCTTCTTTTTTGGATCCATC 
3NLS 
F TCGAGATGGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGGATCCACCGGATCTAGA 
R GATCTCTAGATCCGGTGGATCCTACCTTTCTCTTCTTTTTTGGATCTACCTTTCTCTTCTTTTTTGGATCTACCTTTCTCTTCTTTTTTGGATCCATC 
DEVDG F 
GTACAAGGGAGGCAACAGCGGTGACGAGGTCGACGGTACCTCAGTCGCCACCGGAAGCGAT 
R ATCGCTTCCGGTGGCGACTGAGGTACCGTCGACCTCGTCACCGCTGTTGCCTCCCTT 
HRPLS 
F GTACAAGGATATCAAGCTGAACCCTCCTGATGAGAGTGGCCCCGGCTGCATGAGCTGCAAGTGTGTGCTCTCCTGAGC 
R GGCCGCTCAGGAGAGCACACACTTGCAGCTCATGCAGCCGGGGCCACTCTCATCAGGAGGGTTCAGCTTGATATCCTT 
6KPLS F 
GTACAAGGATATCAAAAAGAAGAAAAAGAAGTGTGTAATTATGTAAGC 
R GGCCGCTTACATAATTACACACTTCTTTTTCTTCTTTTTGATATCCTT 
 
2.2 Cell Culture and transfection 
Murine mammary carcinoma-derived 4T1 cells were cultured in DMEM supplemented 
with 10% heat-inactivated FCS and 2 mM L-Glutamine while murine squamous cell 
carcinoma SCC cells were cultured in GMEM, 10% heat-inactivated FCS, 2 mM L-
Glutamine, 1mM Sodium Pyruvate, Non-essential Amino acids, Vitamins and 0.5 
mg/ml Hygromycin. Both were maintained in a humidified atmosphere at 37°C and 5% 
CO2.  4T1 cells were transiently transfected with pNGD6/pNGN6 and 
pNGDH/pNGNH using Lipofectamine 2000 reagent and left at 37°C and 5% CO2 for 
24 hours prior to experiments. SCC cells were stably transduced with the constructs 
pBABE-NGD6/NGN6 using a retroviral transduction method. Phoenix ecotropic 
(Phoenix eco) cells were seeded 36 hours prior to Lipofectamine transfection with the 
retroviral constructs. The transfection medium was removed 24 hours later and replaced 
with 5 ml of fresh media supplemented with 20% FBS. After 24 hours the viral 
supernatant was collected, filtered through a 0.45µm membrane, and added to target 
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cells in the presence of 4 µg/ml polybrene. This was repeated a further 2 times. Cells 
stably expressing the construct were selected with 1 µg/ml puromycin and the brightest 
cells were single cell FACS on a BD FACSAriaTM II (BD Biosciences) machine. Cells 
were maintained in media containing 1 µg/ml puromycin.  
 
2.3 Confocal microscopy analysis  
Collagen coated coverslips in the bottom of 12 well plates were seeded with cells at a 
density of 1 x 104 in 1 ml growth medium. For assessment of cleavage of the final 
construct, 24 hours post-seeding, 4T1 cells were treated with 4 µM doxorubicin 
(Sigma) and SCC cells with 250 nM staurosporine (Sigma). After 24 hours, cells were 
fixed by the addition of 1 ml 8% paraformaldehyde for 20 minutes, washed once in 
PBS, incubated with Hoechst (1:5000 in PBS) for 10 minutes at room temperature, 
rinsed two further times in PBS and mounted using Vectashield mounting medium 
(Vector Laboratories Ltd). Alternatively, if immunofluorescence of cleaved caspase-3 
(Cell Signaling) was required, following the first PBS wash, cells were incubated in IF 
blocking buffer (PBS containing 1% BSA and 0.2% Triton-X100) for 30 minutes. 
Primary antibody, diluted 1:400 in IF blocking buffer, was added for 1 hour. Cells were 
washed once in IF blocking buffer and incubated in the buffer for 30 minutes. Alexa 
fluor 594 secondary antibody and Hoechst (1:5,000, Invitrogen) diluted in IF blocking 
buffer were added to the wells for 45 minutes in the dark. Cells were washed twice in 
PBS and mounted. Cells were viewed using an Olympus FV1000 confocal microscope. 
For quantification of apoptosis in the SCC NGD6 and NGN6 cells the number of cells 
with nuclear GFP were counted manually in five low magnification images and plotted 
as a function of the total number of cells identified by Hoechst staining. GFP positive 
nuclei were identified by co-localization with a Hoechst signal. Representative images 
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of GFP positive nuclei are shown in Figure 4 (right hand panels). All images were 
scored blinded. Each experiment was performed in triplicate and independently 
repeated three times. 
 
2.4 Western blot analysis 
Cells to be analyzed by western blotting were seeded at an appropriate density in 100 
mm dishes and treated with doxorubicin or staurosporine as indicated. For assessment 
of probe cleavage SCC and SCC NGD6 cells were left untreated, or SCC NGD6 cells 
were exposed to 250 nM staurosporine for 24 hours: lysates from untreated SCC NGD6 
cells were incubated with recombinant Caspase-3 or Cathepsin B (Millipore) for given 
time points. Cell lysis was carried out	with RIPA buffer and protein concentration of 
the supernatants determined using a Micro BCATM protein assay kit (Thermo 
Scientific). Lysates were separated using 4-12% SDS-PAGE gels and 
electrophoretically transferred onto a nitrocellulose membrane. The membrane was 
probed with the desired primary antibody; Cleaved caspase-3 (1:1000, Cell Signaling), 
PARP (1:1000, Cell Signaling), Anti-Tag (CGY)FP (1:10,000 Evrogen) or β-actin 
(1:1000, Sigma). Membranes were subsequently incubated with the relevant Licor 
Anti-mouse 680 or Anti-rabbit 800 secondary antibody and visualized using the LI-
COR Odyssey SA system. 
 
2.5 NucView apoptosis assay 
SCC cells were seeded at a density of 1000 cells/well into Nunc 96 well optical bottom 
plates (Thermo Scientific) with 1 µM NucView (Biotium). After 24 hours cells were 
exposed to increasing concentrations of staurosporine ranging from 7 nM to 1 µM. At 
16, 24, 36 or 48 hours post drug addition, nuclei were stained with Hoechst (1:5000) 
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for 10 minutes at 37°C. Plates were imaged with the Olympus ScanR microscope using 
excitation and emission filter cubes for DAPI and FITC and brightfield using a 20x 
objective. Per well 9 images were taken using a 3 by 3 grid with 800 µm spacing and 
field of view 433 by 330 µm. The DAPI channel was used for autofocus. Images were 
analysed using the ScanR analysis software according to the manufacturer’s 
instructions. Briefly, the number of nuclei and NucView positive objects were 
identified by setting a defined threshold in the DAPI and FITC channels, respectively 
using the ScanR analysis software based on images from both untreated and treated 
cells. Finally, the percentage NucView positive nuclei (where nuclear objects also had 
a NucView object) was calculated in Microsoft Excel.  
 
2.6 ImageXpress high-throughput assay 
SCC cells were seeded in Nunc 96 well optical bottom plates and cultured for 24 
hours. Alternate columns were treated with either DMSO (0.1% final concentration) or 
1000 nM staurosporine and cells cultured for a further 24 hours. Cell nuclei were 
labelled with Hoechst (2 µg/ml; Invitrogen) and plates were imaged on an ImageXpress 
Micro XLS microscope (Molecular Devices) using the DAPI and FITC filters. Images 
were analyzed using CellProfiler [17]: briefly, positive nuclei were identified using an 
Otsu threshold on the Hoechst channel to identify individual cells. For NGD6 and 
NGN6 expressing cells using the nucleus as a seed, a secondary object (the whole cell) 
was derived from the FITC channel and then identified by using the ‘propagation’ 
function. The nuclear object was subtracted from the whole cell to give the cell body 
which represents the non-nuclear signal. Finally, the intensity of the GFP probe in the 
nucleus and the cell body objects was measured. Well averages were calculated from 
single cell data of cell body GFP intensity and normalized as percentage of DMSO 
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controls. For SCC cells treated with NucView (identified as above) were classified as 
NucView positive or negative. Nucview positive nuclei were identified by setting an 
Otsu threshold in the FITC channel to generate a NucView mask. Nuclear objects that 
also had an associated NucView object were classed as apoptotic and expressed as a 
percentage of the population. Data was handled in Excel and GraphPad Prism. A 
D’Agostino and Pearson omnibus K2 test was used to confirm a normal distribution of 
the data (GraphPad Prism). Assay robustness was tested using a Z-factor analysis [18]. 
 
3. Results and discussion 
3.1 Generation of an apoptosis reporter construct named pCasFswitch 
pCasFswitch is a fluorescent based reporter, designed to reveal cells undergoing 
caspase-3 mediated apoptosis. The structure of the reporter is shown in Figure 1A. It 
incorporates a GFP sequence flanked at the N-terminus by a nuclear localization 
sequence (NLS), and at the C-terminus by a plasma membrane localization sequence 
(PLS) separated from the GFP by the caspase-3 cleavage domain (DEVDG). The probe 
is designed on the assumption that the plasma membrane targeting sequence is stronger 
than the nuclear localization sequence. So, the probe will be located at the plasma 
membrane via the PLS, and upon cleavage by caspase-3 at the DEVDG domain 
(between D and G), the GFP-NLS will accumulate in the nucleus. The construct was 
constructed by the stepwise modification of pEGFP-N1 through ligation of synthetic 
oligonucleotides. The first step involved the insertion of NLS at the N-terminal of GFP, 
one containing two NLS repeats, and the other containing three repeats, to generate 
p2NLS-GFP and p3NLS-GFP respectively. The NLS sequence was based on that of 
the Simian Vacuolating Virus 40 (SV40) Large T-antigen [19]. Fluorescence images of 
cells transfected with these intermediate constructs revealed that with two NLS repeats, 
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the reporter was localized both in the nucleus and the cytoplasm. On the contrary with 
three repeats the GFP signal was strongly nuclear, and this construct was therefore 
utilized for subsequent modification (Figure 1B). The second step incorporated one of 
two PLS at the C-terminal of GFP: one took advantage of the hexalysine stretch 
employed by K-Ras4B, and the other was based on the hypervariable domain of H-Ras 
[20, 21], yielding the intermediate constructs pNLS-GFP-6KPLS and pNLS-GFP-
HRPLS respectively. The addition of both PLS resulted in the translocation of the 
majority of the GFP to the plasma membrane, subsequently both constructs were 
completed by the addition of the caspase-3 cleavage domain between the GFP and PLS 
domains to yield two reporter constructs for validation; pNLS-GFP-DEVDG-6KPLS 
and pNLS-GFP-DEVDG-HRPLS (referred to as NGD6 and NGDH from here on) 
(Figure 1B). Addition of the cleavage domain did not affect the cellular distribution of 
GFP (Figure 1B). We also generated non-cleavable reporters in which the aspartic acid 
at the P1 position was changed to an asparagine residue yielding the control constructs 
NGN6 and NGNH ([22-24], Figure 1A). 
 
3.2 Translocation of pCasFswitch to the nucleus following induction of apoptosis 
In order to validate the constructs, conditions that activate the target of the probe 
(caspase-3) in cells needed to be determined. 4T1 cells are derived from a mouse 
mammary tumor and were treated with doxorubicin which is a drug widely utilized for 
the treatment of breast cancer and known to induce apoptosis [25]. To determine the 
doxorubicin concentration required to activate apoptosis, 4T1 cells were treated with 
increasing concentrations of doxorubicin for 24 hours and analyzed by western blotting. 
Western blot analysis of cell lysates from the adherent population showed that cleavage 
of caspase-3, and its downstream substrate poly(ADP-ribose) polymerase (PARP) [8], 
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was achieved at concentrations of 4 µM doxorubicin and above (Figure 2A). The 
timescale of caspase-3 activation was then assessed by exposing cells to 4 µM 
doxorubicin for specified time periods. Western blotting showed that 15 hours was the 
first time point at which cleavage of caspase-3 and PARP had occurred (Figure 2B). 
So, doxorubicin was utilized in vitro at a concentration of 4 µM for 15 hours to activate 
caspase-3 in adhered cells to validate the apoptosis imaging agents. To evaluate the 
generality of the approach an additional cancer cell line and apoptosis-inducing agent 
was employed in this initial validation. The mouse squamous cell carcinoma (SCC) cell 
line [26]) was treated with staurosporine, a drug that is widely utilized to induce 
apoptosis. SCC cells were exposed to increasing concentrations of staurosporine and 
western blot analysis showed that cleavage of caspase-3 was achieved using 
concentrations of 50 nM staurosporine and above (Figure 2C). Activation of caspase-3 
was confirmed with these concentrations by the cleavage of its downstream substrate 
PARP (Figure 2C). Exposure of the cells to 250 nM staurosporine for specified time 
periods showed that the cleavage of caspase-3 and PARP could be detected at 15 hours 
post exposure (Figure 2D). So, staurosporine was used in vitro at a concentration of 
250 nM for a minimum of 15 hours. 
Once general parameters to activate caspase-3 in the 4T1 and SCC cells were 
established we then looked at the localization of pCasFswitch following induction of 
apoptosis. In the majority of untreated 4T1 cells expressing NGD6, GFP was localized 
predominantly at the plasma membrane. A few cells with nuclear GFP were evident, 
however, upon doxorubicin treatment the number of cells expressing nuclear GFP 
increased (Figure 3A). Similar observations were made in 4T1 cells transfected with 
the NGDH construct although there were low levels of cytoplasmic staining in both 
untreated and treated cells (Figure 3B). The NGD6 construct was therefore taken 
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forward for further analysis in SCC cells following stable expression of the constructs. 
Fluorescence images of untreated SCC NGD6 expressing cells showed GFP was 
localized predominantly at the plasma membrane, and very occasionally, a few cells 
with some nuclear GFP were evident (Figure 4). Upon incubation of the cells with 250 
nM staurosporine for 24 hours, the number of cells that contained nuclear GFP 
increased (Figure 4). Use of a cleaved caspase-3 antibody confirmed that cells with 
nuclear GFP were expressing cleaved caspase-3 (Figure 4, bottom panels). 
 
3.3 pCasFswitch is cleaved by caspase-3 
Characterization of pCasFswitch cleavage by recombinant caspase-3 was carried out. 
SCC NGD6 cells were left untreated, or treated with 250 nM staurosporine for 24 hours, 
and lysates subjected to western blot analysis using a GFP antibody. NGD6 expressing 
cells would be expected to generate two GFP bands on a western blot; one for the un-
cleaved probe at 34 kDa, and the other for the cleaved probe at 31 kDa (Figure 5A). 
Only a 34 kDa band was evident in untreated cells corresponding to the un-cleaved 
probe, the level of which decreased upon staurosporine treatment, with the concomitant 
appearance of a 31 kDa band corresponding to the cleaved probe (Figure 5B). The 
absence of bands upon exposure of SCC lysates to the GFP antibody confirmed the 
presence of bands in SCC NGD6 lysates were specific to the construct. Incubation of 
SCC NGD6 lysates with recombinant caspase-3 (C3) for various times, but not 
Cathepsin B (CB), resulted in the appearance of the 31 kDa cleavage product, and 
confirmed the construct was cleaved by caspase-3 and could not be cleaved by other 
members of the cysteine protease family of proteins. Probing of the membranes with 
the cleaved caspase-3 antibody confirmed all construct cleavage was occurring with the 
presence of active caspase-3, with differences in the molecular weight of the bands 
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detected corresponding to the native and recombinant protein respectively. The 
observation of PARP cleavage under these conditions further confirmed the activity of 
the recombinant caspase-3 in the lysates (Figure 5B). 
 
3.4 Cleavage of pCasFswitch is required for translocation to the nucleus 
To determine whether caspase-3 dependent cleavage of pCasFswitch was required for 
its translocation to the nucleus we looked at localization of the non-cleavable NGN6 
reporter (Figure 1A). In SCC NGN6 expressing cells, GFP was localized at the plasma 
membrane in untreated cells, and no translocation of GFP to the nucleus was evident in 
staurosporine treated cells (Figure 6). Caspase-3 activation in the staurosporine treated 
cells was confirmed by the presence of cleaved caspase-3 in the cells detected by 
immunofluorescence (Figure 6). 
 
3.5 Quantitative analysis of apoptosis using pCasFswitch 
To provide a quantitative read-out of apoptosis SCC NGD6 and NGN6 expressing cells 
were either left untreated or treated with 250 nM staurosporine for 24 hours. The 
number of cells in which GFP was present in the nucleus was then calculated in five 
low magnification images. The number of GFP nuclear cells were counted and plotted 
as a function of the total number of cells identified by Hoechst staining. Each 
experiment was performed in triplicate, to allow identification of inter well anomalies, 
and the mean calculated. Nuclear GFP fluorescence was evident in 22.6 % of 
staurosporine treated SCC NGD6 cells, and 0% of staurosporine treated cells 
expressing the non-cleavable NGN6 construct (Figure 7A). This is in good agreement 
(p = 0.1966 by Student’s t test) with the mean of 20.3 % apoptotic cells identified using 
NucView over three independent experiments (Figure 7B). NucView employs a 
Page 14 of 30AUTHOR SUBMITTED MANUSCRIPT - MAF-100474.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 Ac
ce
pte
d M
an
us
cri
pt
	 15	
fluorogenic enzyme substrate design in which a nucleic acid dye is attached to the 
caspase-3/7 substrate peptide sequence DEVD. In this linked state, the dye is unable to 
bind DNA and remains non-fluorescent. Once the substrate becomes cleaved, the 
NucView 488 DNA dye can migrate to the nucleus, and upon binding DNA yields a 
bright green fluorescence [27]. 
To further validate the probe for high-throughput analysis we used the ImageXpress 
high-content analysis system widely used in high-throughput drug screening pipelines 
[28]. Analysis of multiple 96-well plates demonstrated excellent inter-plate 
reproducibility (Figure 8A) and comparison of the quantitative analysis of apoptosis 
using the NGD6 reporter and NucView showed good agreement between the two 
approaches. Furthermore, calculation of the Z-factor for the NGD6 reporter assay, 
which is used in high-throughput screening as a measure of statistical effect size was 
excellent (Z = 0.81) (Figure 8A). 
 
4. Conclusions 
In conclusion, we have developed a novel genetically encoded fluorescent apoptosis 
reporter construct designed to identify cells undergoing caspase-3 mediated apoptosis 
through translocation of a GFP construct from the cell membrane into the nucleus. 
Other apoptosis reporters, based on translocation of GFP to the nucleus following 
caspase cleavage have been generated. Bardet and co-workers used a caspase sensitive 
site from the caspase inhibitor Drosophila inhibitor of apoptosis protein 1 (DIAP1) 
rather than the DEVD sequence used in pCasFSwitch [11]. DIAP1 is cleaved by 
downstream effector caspases and was also shown to be an effective read-out of caspase 
activation. However, in untreated cells nuclear GFP was evident in all cells [11] and to 
overcome this limitation we incorporated a PLS which effectively excluded GFP from 
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the nucleus (Figure 1). Previous studies have also reported low signal-to-noise ratios 
due to significant retention of GFP in the cytoplasm of apoptotic cells [13-15]. This 
raised the possibility that the single NLS sequence used in these reporters was not 
sufficient for the robust nuclear localization of GFP upon caspase-dependent cleavage. 
Indeed, we show that the addition of 3 NLS sequences increased the nuclear localization 
of GFP as compared to a single NLS (Figure 1).  However, we did still see evidence of 
non-nuclear GFP and indeed within the cytoplasm of apoptotic cells. The high 
expression of pCasFSwitch in cells coupled with the tendency of GFP to distribute to 
the cytoplasm  [15] may account for this distribution pattern. However, importantly we 
were able to demonstrate the utility of pCasFSwitch for higher throughput modalities 
providing robust quantitative measurements based on its translocation in apoptotic 
cells. We envisage that pCasFSwitch can provide a powerful preclinical drug 
development tool, enabling interrogation of drug effects in live single cells in real-time 
after a simple transfection providing a cheaper alternative to the use of agents such as 
NucView or antibody-based approaches. Nicholls and co-workers have developed a 
caspase activity reporter based on the use of a genetically encoded GFP fused to a 
peptide which quenches the fluorescence signal. Incorporation of a DEVD cleavage site 
allows removal of the quenching peptide upon caspase activation and results in 
increased GFP fluorescence and provides a more direct read-out of apoptosis that does 
not depend on nuclear translocation [12]. Direct comparison with pCasFSwitch would 
be required to determine whether this provides a more robust approach for use in high-
throughput imaging systems. Previous studies have shown that imaging of apoptosis 
can be achieved based on direct visualization of nuclear fragmentation, that occurs 
during the apoptotic process, using  cells expressing histone H2B-GFP in the nucleus 
[29, 30]. This provides a useful qualitative read-out of different stages of the apoptotic 
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process in real-time although quantitative measurements for high-throughput assays 
would be difficult. Further developments could see the use of pCasFSwitch extended 
to the in vivo environment, allowing extrapolation of in vitro and in vivo data. Indeed, 
we have shown the utility of a genetically encoded photoactivatable two-color probe 
for real-time tracking of cells in Drosophila [19]. The use of intravital imaging to 
provide subcellular distribution of proteins in mouse models opens up the possibility of 
tracking apoptosis in real time in vivo [31].   
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Figure Legends 
Figure 1. Design and generation of pCasFSwitch. (A) pCasFSwitch is a fluorescent 
reporter construct designed to identify cells undergoing caspase-3 mediated apoptosis 
by a switch in a GFP signal from the plasma membrane of the cell to the nucleus. 
Schematic representations of the constructs showing the caspase-3 cleavage site in red. 
Probe nomenclature shown beside each schematic. (B) pCasFSwitch was constructed 
from pEGFP-N1. Step 1: insertion of two or three nuclear localization sequences (NLS) 
at the N-terminal of GFP, to generate p2NLS-GFP and p3NLS-GFP respectively. White 
arrows indicate nuclear GFP, and white arrowheads show cytosolic GFP. Step 2: 
insertion of plasma membrane localization sequences (PLS) at the C-terminal of GFP, 
using the hexalysine stretch employed by K-Ras4B, or the hypervariable domain of H-
Ras, yielding the intermediate constructs pNLS-GFP-6KPLS and pNLS-GFP-HRPLS 
respectively. Step3: insertion of the caspase-3 cleavage domain between GFP and the 
PLS to generate the final constructs, pNLS-GFP-DEVDG-6KPLS (NGD6) and pNLS-
GFP-DEVDG-HRPLS (NGDH). Functionality testing for each of the constructs was 
carried out by transient transfection into HEK293T cells and analysis by confocal 
microscopy. Representative images for each of the intermediate constructs is shown 
below the appropriate construct schematic. Blue = nuclei stained with Hoechst; Green 
= cellular distribution of the GFP construct. Merge = overlay of blue and green channels 
superimposed on DIC image. Scale bars = 10 µm.  
 
Figure 2. Activation of caspase-3 in 4T1 and SCC cells. (A) Cell lysates from 4T1 cells 
treated with increasing concentrations of doxorubicin for 24 hours, or (B) 4T1 cells 
treated with 4 µM doxorubicin for given time periods, or (C) SCC cells treated with 
increasing concentrations of staursporine for 24 hours, or (D) SCC cells treated with 
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250 nM staurosporine for given time periods, were subjected to western blot analysis 
using cleaved caspase-3 and PARP antibodies. All membranes were stripped and re-
probed with β-actin as a loading control.  
 
Figure 3. Cellular distribution of NGD6 and NGDH in 4T1 cells. Representative 
confocal images of (A) 4T1 NGD6 cells and (B) 4T1 NGDH cells untreated or treated 
with 4 µM doxorubicin for 15 hours. Blue = nuclei stained with Hoechst; Green = 
cellular distribution of GFP construct; Merge = overlay of channels. Scale bars = 10 
µm.  
 
Figure 4. Cellular distribution of NGD6 in SCC cell line. Representative confocal 
images of SCC NGD6 cells untreated or treated with 250 nM staurosporine for 24 hours 
(STS). Blue = nuclei stained with Hoechst; Green = cellular distribution of GFP 
construct; Red = Cleaved caspase-3 immunofluorescence; Merge = overlay of channels. 
Scale bars = 10 µm.  
 
Figure 5. Cleavage analysis of NGD6 in SCC cell line. (A) Schematic representation 
of caspase-3 mediated cleavage of NGD6 showing the un-cleaved and cleaved 
structures. Probe nomenclature and molecular weight shown beside each schematic. 
(B) Lysates from; SCC cells, SCC NGD6 cells left untreated or treated with 250 nM 
staurosporine for 24 hours (STS), and untreated SCC NGD6 cells incubated with 
recombinant caspase-3 (C3) or Cathepsin B (CB) for given time periods (as indicated), 
were subjected to western blot analysis using GFP, cleaved caspase-3 and PARP 
antibodies. All membranes were stripped and re-probed with β-actin as a loading 
control. 
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Figure 6. Cellular distribution of NGN6 in SCC cell line. Representative confocal 
images of SCC NGN6 cells untreated or treated with 250 nM staurosporine for 24 hours 
(STS). Blue = nuclei stained with Hoechst; Green = cellular distribution of GFP 
construct; Red = Cleaved caspase-3 immunofluorescence; Merge = overlay of both 
channels. Scale bars = 10 µm.  
 
Figure 7. Quantification of staurosporine mediated apoptosis using SCC NGD6 and 
NGN6 cells. (A) Percentage of cells with nuclear GFP calculated for the constructs and 
treatment conditions indicated. STS = treatment with 250 nM staurosporine for 24 
hours. Black bars represent the mean of one experiment performed in triplicate, green 
bars represent the mean of three independent experiments +/- SD. (B) Percentage 
NucView positive cells calculated for the treatment conditions indicated. STS= 
treatment with 250 nM staurosporine for 24 hours. Black bars represent the mean of 
one experiment performed in triplicate, green bars represent the mean of three 
independent experiments +/- S.D.  
 
Figure 8. Quantification of staurosporine mediated apoptosis using ImageXpress. (A) 
SCC NGD6 or SCC NGN6 cells treated with staurosporine (STS) for 24 hours. SCC 
cells incubated with NucView apoptosis reagent were included as a comparison. Graphs 
represent column averages from each 96 well plate ± standard deviation. A Z-factor 
(Z’) analysis was performed on each plate. (B) Representative images of SCC NGD6 
and SCC NGN6 cells or NucView treated SCC cells +/- staurosporine for 24 hours. 
Blue = nuclei stained with Hoechst; Green = cellular distribution of GFP construct or 
NucView. Scale bar = 20 µm. 
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